Innate Pharma (IPHA) — Net Asset Quality Index
Innate Pharma (IPHA) has a Net Asset Quality Index of -34.6% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $62.69 Million minus total liabilities of $84.39 Million yields net assets of $-21.69 Million. A higher index indicates a stronger, lower-leverage balance sheet. See IPHA days of operational coverage to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Innate Pharma Net Asset Quality Index Over Time (2005–2025)
This chart shows how Innate Pharma's Net Asset Quality Index has evolved across 21 annual periods from 2005 to 2025. As of March 2026, the index stands at -34.6%, representing net assets of $-21.69 Million against total assets of $62.69 Million USD. Explore IPHA cash flow conversion to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Innate Pharma (2005–2025)
The table below presents the year-by-year Net Asset Quality Index for Innate Pharma from 2005 to 2025, covering 21 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see IPHA company net worth.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | -34.6% | $-21.69 Million | $62.69 Million | $84.39 Million | ▼ -42.6 pp |
| 2024 | 8.0% | $8.83 Million | $111.06 Million | $102.22 Million | ▼ -16.5 pp |
| 2023 | 24.5% | $42.90 Million | $175.19 Million | $132.29 Million | ▼ -1.6 pp |
| 2022 | 26.1% | $54.15 Million | $207.86 Million | $153.71 Million | ▼ -14.1 pp |
| 2021 | 40.2% | $107.44 Million | $267.50 Million | $160.06 Million | ▼ -10.6 pp |
| 2020 | 50.7% | $155.97 Million | $307.42 Million | $151.45 Million | ▼ -3.4 pp |
| 2019 | 54.2% | $217.42 Million | $401.36 Million | $183.94 Million | ▲ +17.1 pp |
| 2018 | 37.1% | $167.24 Million | $451.22 Million | $283.98 Million | ▲ +3.4 pp |
| 2017 | 33.7% | $85.96 Million | $255.02 Million | $169.07 Million | ▲ +3.1 pp |
| 2016 | 30.6% | $86.17 Million | $281.58 Million | $195.41 Million | ▲ +7.0 pp |
| 2015 | 23.6% | $72.07 Million | $305.96 Million | $233.89 Million | ▼ -58.7 pp |
| 2014 | 82.3% | $74.63 Million | $90.69 Million | $16.06 Million | ▲ +10.2 pp |
| 2013 | 72.1% | $40.29 Million | $55.88 Million | $15.60 Million | ▲ +23.7 pp |
| 2012 | 48.4% | $23.36 Million | $48.30 Million | $24.93 Million | ▲ +4.1 pp |
| 2011 | 44.3% | $26.62 Million | $60.11 Million | $33.48 Million | ▼ -25.5 pp |
| 2010 | 69.8% | $33.52 Million | $48.01 Million | $14.49 Million | ▼ -3.6 pp |
| 2009 | 73.4% | $47.12 Million | $64.22 Million | $17.10 Million | ▲ +5.5 pp |
| 2008 | 67.9% | $41.34 Million | $60.86 Million | $19.52 Million | ▼ -10.6 pp |
| 2007 | 78.5% | $49.61 Million | $63.15 Million | $13.55 Million | ▼ -2.8 pp |
| 2006 | 81.4% | $56.37 Million | $69.25 Million | $12.89 Million | ▲ +0.4 pp |
| 2005 | 81.0% | $20.07 Million | $24.77 Million | $4.70 Million | — |